Results 161 to 163 of about 7,486 (163)

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

Multiple Sclerosis and Related Disorders, 2020
Louisa K James, Monica Marta, David Baker   +2 more
exaly  

Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review

Expert Opinion on Drug Safety, 2020
Helen Tremlett, Huah Shin Ng
exaly  

Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis

Histopathology
Ashwini K Esnakula, Bindu Challa
exaly